Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Bleeding disorders in adolescents with heavy menstrual bleeding in a multicentre prospective US cohort.

Zia A, Jain S, Kouides P, Zhang S, Gao A, Salas N, Lau M, Wilson E, DeSimone N, Sarode R.

Haematologica. 2019 Oct 17. pii: haematol.2019.225656. doi: 10.3324/haematol.2019.225656. [Epub ahead of print]

2.

When age is truly only a number: late diagnosis of von Willebrand disease type 2B in a 61-year-old woman.

Singal M, Kouides PA.

Blood Coagul Fibrinolysis. 2019 Oct;30(7):361-363. doi: 10.1097/MBC.0000000000000847.

PMID:
31464689
3.

Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world.

Aryal MR, Gosain R, Donato A, Yu H, Katel A, Bhandari Y, Dhital R, Kouides PA.

Blood Adv. 2019 Aug 13;3(15):2381-2387. doi: 10.1182/bloodadvances.2019000572. Review.

4.

Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor.

Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E.

Blood Rev. 2019 Nov;38:100572. doi: 10.1016/j.blre.2019.04.001. Epub 2019 Apr 3. Review.

5.

Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.

Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ.

Haemophilia. 2019 Jul;25(4):668-675. doi: 10.1111/hae.13758. Epub 2019 Apr 17.

PMID:
30993845
6.

Defining Minimum Necessary Anticoagulation-Related Communication at Discharge: Consensus of the Care Transitions Task Force of the New York State Anticoagulation Coalition.

Triller D, Myrka A, Gassler J, Rudd K, Meek P, Kouides P, Burnett AE, Spyropoulos AC, Ansell J.

Jt Comm J Qual Patient Saf. 2018 Nov;44(11):630-640. doi: 10.1016/j.jcjq.2018.04.015. Epub 2018 Jul 24.

PMID:
30064950
7.

A cross-sectional analysis of cardiovascular disease in the hemophilia population.

Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang TF, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Wheeler A, Kouides P, Escobar MA, Leissinger C, Galdzicka S, Corson M, Watson C, Konkle BA.

Blood Adv. 2018 Jun 12;2(11):1325-1333. doi: 10.1182/bloodadvances.2018018226.

8.

Prospective analysis of bleeding events in left ventricular assist device patients.

Sherazi S, Kouides P, Francis C, Lowenstein CJ, Refaai M, Conley G, Johnson BA, Muchnik E, Lien S, Massey HT, Alexis JD.

Int J Artif Organs. 2018 May;41(5):269-276. doi: 10.1177/0391398818762353. Epub 2018 Mar 22.

PMID:
29562808
9.

Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.

Kouides PA.

Blood Adv. 2017 Apr 25;1(11):699-702. doi: 10.1182/bloodadvances.2017005082. eCollection 2017 Apr 25.

10.

The spectrum of bleeding in women and girls with haemophilia B.

Staber J, Croteau SE, Davis J, Grabowski EF, Kouides P, Sidonio RF Jr.

Haemophilia. 2018 Mar;24(2):180-185. doi: 10.1111/hae.13376. Epub 2017 Nov 27. Review.

PMID:
29178325
11.

Outgrowing the laboratory diagnosis of type 1 von Willebrand disease: A two decade study.

Abou-Ismail MY, Ogunbayo GO, Secic M, Kouides PA.

Am J Hematol. 2018 Feb;93(2):232-237. doi: 10.1002/ajh.24962. Epub 2017 Nov 17.

12.

Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding.

Srivaths LV, Zhang QC, Byams VR, Dietrich JE, James AH, Kouides PA, Kulkarni R; Hemophilia Treatment Centers Network Investigators.

Haemophilia. 2018 Jan;24(1):63-69. doi: 10.1111/hae.13330. Epub 2017 Sep 5.

13.

Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.

Kouides P, Wawra-Hehenberger K, Sajan A, Mead H, Simon T.

Transfusion. 2017 Oct;57(10):2390-2403. doi: 10.1111/trf.14241. Epub 2017 Jul 10.

PMID:
28691218
14.

Feasibility of the Von Willebrand disease PREVENT trial.

Ragni MV, Machin N, James AH, Seaman CD, Malec LM, Kessler CM, Konkle BA, Kouides PA, Neff AT, Philipp CS, Brooks MM.

Thromb Res. 2017 Aug;156:8-13. doi: 10.1016/j.thromres.2017.05.022. Epub 2017 May 25.

PMID:
28577390
15.

Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease.

Singal M, Kouides PA.

Drugs Today (Barc). 2016 Dec;52(12):653-664. doi: 10.1358/dot.2016.52.12.2570978. Review.

PMID:
28276537
16.

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR.

Haemophilia. 2017 Mar;23(2):198-206. doi: 10.1111/hae.13178. Epub 2017 Jan 25.

PMID:
28124511
17.

The scope and value of an anticoagulation stewardship program at a community teaching hospital.

Wychowski MK, Ruscio CI, Kouides PA, Sham RL.

J Thromb Thrombolysis. 2017 Apr;43(3):380-386. doi: 10.1007/s11239-016-1455-z.

PMID:
27878507
18.

Present day management of inherited bleeding disorders in pregnancy.

Kouides PA.

Expert Rev Hematol. 2016 Oct;9(10):987-95. doi: 10.1080/17474086.2016.1216312. Epub 2016 Aug 2. Review.

PMID:
27459638
19.

Use of donated clotting factors for surgeries on haemophilic patients in a resource-constrained country: a kind donor, good outcome, change of practice and future directions.

Poudyal BS, Shrestha GS, Tuladhar S, Gyawali B, Sedain G, Battajo R, Maskey P, Paudyal S, Regmi S, Rc DR, Kouides P.

Haemophilia. 2016 Sep;22(5):e453-5. doi: 10.1111/hae.13017. Epub 2016 Jun 28. No abstract available.

PMID:
27353411
20.

Von Willebrand factor for menorrhagia: a survey and literature review.

Ragni MV, Machin N, Malec LM, James AH, Kessler CM, Konkle BA, Kouides PA, Neff AT, Philipp CS, Brambilla DJ.

Haemophilia. 2016 May;22(3):397-402. doi: 10.1111/hae.12898. Epub 2016 Feb 4. Review.

21.

Developing a multidisciplinary Young Women's Blood Disorders Program: a single-centre approach with guidance for other centres.

Zia A, Lau M, Journeycake J, Sarode R, Marshall J, De Simone N, Wilson E, Winborn A, Kouides P.

Haemophilia. 2016 Mar;22(2):199-207. doi: 10.1111/hae.12836. Epub 2016 Jan 29.

PMID:
26822547
22.

Validation Study of the Composite Score to Identify Von Willebrand Disease in Children.

Malec LM, Moore CG, Bennett CM, Yee DL, Kerlin BA, Witmer CM, Kulkarni R, Gupta S, Gunawardena S, Kouides PA, Brown D, Ragni MV.

J Pediatr Hematol Oncol. 2016 Mar;38(2):139-42. doi: 10.1097/MPH.0000000000000460.

PMID:
26535774
23.

Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.

Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, Obermann-Slupetzky O, Chapman M, Fritsch S, Pavlova BG, Presch I, Ewenstein B.

Blood. 2015 Oct 22;126(17):2038-46. doi: 10.1182/blood-2015-02-629873. Epub 2015 Aug 3. Erratum in: Blood. 2016 Jun 2;127(22):2777.

24.

An update on the management of bleeding disorders during pregnancy.

Kouides PA.

Curr Opin Hematol. 2015 Sep;22(5):397-405. doi: 10.1097/MOH.0000000000000167. Review.

PMID:
26164463
25.

Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.

Abshire T, Cox-Gill J, Kempton CL, Leebeek FW, Carcao M, Kouides P, Donfield S, Berntorp E.

J Thromb Haemost. 2015 Sep;13(9):1585-9. doi: 10.1111/jth.12995. Epub 2015 Jul 14. Review.

26.

Preventing postpartum haemorrhage-when guidelines fall short.

Kouides PA.

Haemophilia. 2015 Jul;21(4):502-4. doi: 10.1111/hae.12661. Epub 2015 Apr 30. No abstract available.

PMID:
25929422
27.

Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.

Holm E, Abshire TC, Bowen J, Álvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E.

Blood Coagul Fibrinolysis. 2015 Jun;26(4):383-8. doi: 10.1097/MBC.0000000000000257.

PMID:
25688461
28.

Safe and effective use of chronic transdermal estradiol for life-threatening uremic bleeding in a patient with coronary artery disease.

Bali A, Hix JK, Kouides P.

Nephron Extra. 2014 Aug 19;4(2):134-7. doi: 10.1159/000365480. eCollection 2014 May.

29.

Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis.

James AH, Konkle BA, Kouides P, Ragni MV, Thames B, Gupta S, Sood S, Fletcher SK, Philipp CS.

Haemophilia. 2015 Jan;21(1):81-7. doi: 10.1111/hae.12568. Epub 2014 Oct 21.

30.

Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR Task Force of the New York State Anticoagulation Coalition.

Spyropoulos AC, Viscusi A, Singhal N, Gilleylen J, Kouides P, Howard M, Rudd K, Ansell J, Triller DM.

Ann Pharmacother. 2015 Jan;49(1):113-24. doi: 10.1177/1060028014555176. Epub 2014 Oct 16.

PMID:
25325906
31.

Evaluation and management of postpartum hemorrhage: consensus from an international expert panel.

Abdul-Kadir R, McLintock C, Ducloy AS, El-Refaey H, England A, Federici AB, Grotegut CA, Halimeh S, Herman JH, Hofer S, James AH, Kouides PA, Paidas MJ, Peyvandi F, Winikoff R.

Transfusion. 2014 Jul;54(7):1756-68. doi: 10.1111/trf.12550. Epub 2014 Mar 12. Erratum in: Transfusion. 2015 Mar;55(3):691.

PMID:
24617726
32.

Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).

Abshire TC, Federici AB, Alvárez MT, Bowen J, Carcao MD, Cox Gill J, Key NS, Kouides PA, Kurnik K, Lail AE, Leebeek FW, Makris M, Mannucci PM, Winikoff R, Berntorp E; VWD PN.

Haemophilia. 2013 Jan;19(1):76-81. doi: 10.1111/j.1365-2516.2012.02916.x. Epub 2012 Jul 23.

33.

How we manage prostate biopsy and prostate cancer therapy in men with haemophilia.

Fogarty PF, Kouides P.

Haemophilia. 2012 May;18(3):e88-90. doi: 10.1111/j.1365-2516.2012.02787.x. Epub 2012 Apr 16.

PMID:
22500858
34.

Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.

Wychowski MK, Kouides PA.

Ann Pharmacother. 2012 Apr;46(4):e10. doi: 10.1345/aph.1Q747. Epub 2012 Apr 10.

PMID:
22496474
35.

Introductory remarks for the THSNA meeting proceedings: hemostasis and thrombosis at the cutting edge.

Garcia D, Van Cott EM, Kouides PA.

Am J Hematol. 2012 May;87 Suppl 1:S1. doi: 10.1002/ajh.23181. Epub 2012 Apr 4. No abstract available.

36.

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Am J Hematol. 2012 May;87 Suppl 1:S141-5. doi: 10.1002/ajh.23202. Epub 2012 Apr 4. Review. Erratum in: Am J Hematol. 2012 Jul;87(7):748.

37.

Challenges of rare disease research: limited patients and competing priorities.

Ragni MV, Moore CG, Bias V, Key NS, Kouides PA, Francis CW; Hemostasis Thrombosis Research Society (HTRS).

Haemophilia. 2012 May;18(3):e192-4. doi: 10.1111/j.1365-2516.2011.02646.x. Epub 2011 Sep 13.

PMID:
21910791
38.

The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.

Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld EJ, Rodriguez N, Wicklund B, Quon D, Aledort L.

J Thromb Haemost. 2011 Nov;9(11):2229-34. doi: 10.1111/j.1538-7836.2011.04493.x.

39.

Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres.

Byams VR, Kouides PA, Kulkarni R, Baker JR, Brown DL, Gill JC, Grant AM, James AH, Konkle BA, Maahs J, Dumas MM, McAlister S, Nance D, Nugent D, Philipp CS, Soucie JM, Stang E; Haemophilia Treatment Centres Network Investigators.

Haemophilia. 2011 Jul;17 Suppl 1:6-13. doi: 10.1111/j.1365-2516.2011.02558.x.

40.

Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel.

James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, Halimeh S, Kamphuisen PW, Lee CA, Martínez-Perez O, McLintock C, Peyvandi F, Philipp C, Wilkinson J, Winikoff R.

Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):124-34. doi: 10.1016/j.ejogrb.2011.04.025. Epub 2011 Jun 1. Review.

PMID:
21632169
41.

Screening for von Willebrand disease in children: a case-control study.

Bujnicki HC, Sidonio RF, Kempton C, Kouides PA, Kulkarni R, Nugent DJ, Yee DL, Moore CG, Ragni MV.

J Thromb Haemost. 2011 May;9(5):1086-9. doi: 10.1111/j.1538-7836.2011.04261.x. No abstract available.

42.

Tranexamic acid: a novel oral formulation for the treatment of heavy menstrual bleeding.

Lukes AS, Kouides PA, Moore KA.

Womens Health (Lond). 2011 Mar;7(2):151-8. doi: 10.2217/whe.11.9. Review.

PMID:
21410342
43.

Hormonal influences on hemostasis in women.

Trigg DE, Wood MG, Kouides PA, Kadir RA.

Semin Thromb Hemost. 2011 Feb;37(1):77-86. doi: 10.1055/s-0030-1270074. Epub 2011 Jan 19. Review.

PMID:
21249605
44.

Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia.

Philipp CS, Faiz A, Heit JA, Kouides PA, Lukes A, Stein SF, Byams V, Miller CH, Kulkarni R.

Am J Obstet Gynecol. 2011 Mar;204(3):209.e1-7. doi: 10.1016/j.ajog.2010.10.897. Epub 2011 Jan 17.

45.

The spectrum of haemostatic characteristics of women with unexplained menorrhagia.

Miller CH, Philipp CS, Stein SF, Kouides PA, Lukes AS, Heit JA, Byams VR, Dowling NF, Kulkarni R.

Haemophilia. 2011 Jan;17(1):e223-9. doi: 10.1111/j.1365-2516.2010.02382.x. Epub 2010 Oct 6.

PMID:
21040234
46.

von Willebrand disease in the pediatric and adolescent population.

Mikhail S, Kouides P.

J Pediatr Adolesc Gynecol. 2010 Dec;23(6 Suppl):S3-10. doi: 10.1016/j.jpag.2010.08.005.

PMID:
20934894
47.

Update on perioperative bridging in patients on chronic oral anticoagulation.

Faltas B, Kouides PA.

Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1533-9. doi: 10.1586/erc.09.128. Review.

PMID:
19954315
48.

Diagnosis and management of inherited von Willebrand disease in the next decade: panel discussion.

Kouides P, Federici AB, James AH, Berntorp E, Abshire T, Kreuz W.

Thromb Res. 2009 Nov;124 Suppl 1:S20-1. doi: 10.1016/S0049-3848(09)70154-9. No abstract available.

PMID:
19944258
49.

Diagnosis and management of inherited von Willebrand disease in the next decade: a clinical perspective.

Kouides P, Kreuz W.

Thromb Res. 2009 Nov;124 Suppl 1:S1. doi: 10.1016/S0049-3848(09)00520-9. No abstract available.

PMID:
19944254
50.

How do we treat: upper gastrointestinal bleeding in adults with haemophilia.

Kouides PA, Fogarty PF.

Haemophilia. 2010 Mar;16(2):360-2. doi: 10.1111/j.1365-2516.2009.02130.x. Epub 2009 Oct 29. No abstract available. Erratum in: Haemophilia.2010 Mar;16(2):413.

PMID:
19878336

Supplemental Content

Loading ...
Support Center